



12c  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

BAUMANN et al.


Serial No. 08/718,377

Filed: September 30, 1996

For: THE USE OF CARBOXYLIC ACID DERIVATIVES AS DRUGS

Group Art Unit: 1205

Examiner: Jones



#4/C  
JRP  
8/8/97

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231, on:

July 14, 1997

Date of Deposit Henry R. Jiles

Person Making Deposit

Signature July 14, 1997

Date of Signature

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

AMENDMENT UNDER 37 CFR 1.111


Sir:

In response to the office action dated June 20, 1997, kindly enter the following amendment.

IN THE CLAIMS

Amend claim 1 as shown:

1. (amended) [The use of carboxylic acid derivatives of the]  
A method of inhibiting endothelin receptors by administering to a  
patient a compound of the formula I



where R is formyl, CO<sub>2</sub>H or a radical which can be hydrolyzed to COOH, and the remaining substituents have the following meanings:

R<sup>2</sup> is halogen, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy or C<sub>1</sub>-C<sub>4</sub>-alkylthio;

X is nitrogen or CR<sup>14</sup> where R<sup>14</sup> is hydrogen or, together with R<sup>3</sup>, forms a 3- or 4-membered alkylene or alkenylene chain in which, in each case, one methylene group is replaced by oxygen;

45